Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 8.9%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was down 8.9% during mid-day trading on Wednesday . The company traded as low as $21.31 and last traded at $21.33. Approximately 134,878 shares changed hands during trading, a decline of 7% from the average daily volume of 145,499 shares. The stock had previously closed at $23.42.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on DNTH shares. Raymond James lifted their price objective on Dianthus Therapeutics from $34.00 to $51.00 and gave the company an “outperform” rating in a report on Thursday, April 18th. Jefferies Financial Group lifted their price objective on Dianthus Therapeutics from $22.00 to $39.00 and gave the company a “buy” rating in a report on Friday, March 22nd. Wedbush lifted their price objective on Dianthus Therapeutics from $24.00 to $33.00 and gave the company an “outperform” rating in a report on Friday, March 22nd. Finally, Stifel Nicolaus started coverage on Dianthus Therapeutics in a report on Thursday, February 15th. They set a “buy” rating and a $44.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $42.40.

Dianthus Therapeutics Stock Up 2.4 %

The stock has a fifty day moving average of $25.71 and a 200-day moving average of $17.50.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.40. The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.73 million. On average, research analysts predict that Dianthus Therapeutics, Inc. will post -1.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC acquired a new stake in Dianthus Therapeutics in the fourth quarter worth about $25,000. Citigroup Inc. acquired a new stake in Dianthus Therapeutics in the third quarter worth about $53,000. Acadian Asset Management LLC acquired a new stake in Dianthus Therapeutics in the third quarter worth about $303,000. Laurion Capital Management LP acquired a new stake in Dianthus Therapeutics in the third quarter worth about $497,000. Finally, Octagon Capital Advisors LP increased its position in Dianthus Therapeutics by 15.4% in the fourth quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock worth $5,762,000 after purchasing an additional 74,000 shares during the period. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.